Lynx1 Capital Management LP Theseus Pharmaceuticals, Inc. Transaction History

Lynx1 Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.66 - $10.04 $145,220 - $548,123	-54,594 Reduced 7.21%	702,415 $1.89 Million
Q2 2023 Aug 14, 2023	SELL	$7.28 - $11.82 $30,932 - $50,223	-4,249 Reduced 0.56%	757,009 $7.06 Million
Q1 2023 May 15, 2023	SELL	$5.21 - $14.05 $119,309 - $321,745	-22,900 Reduced 2.92%	761,258 $6.76 Million
Q4 2022 Feb 14, 2023	BUY	$4.69 - $8.36 $1.31 Million - $2.33 Million	279,296 Added 55.32%	784,158 $3.91 Million
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $746,096 - $2.08 Million	148,035 Added 41.49%	504,862 $2.79 Million

Q1 2022 May 16, 2022	SELL	$8.75 - $14.51 $459,646 - $762,224	-52,531 Reduced 12.83%	356,827 $4.11 Million
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $3.68 Million - $8.22 Million	409,358 New	409,358 $5.19 Million

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.